Abstract
Personalized cancer treatment can significantly extend survival and improve quality of life for many patients, but accurate and real-time therapy response monitoring remains challenging. To overcome logistical and technical challenges associated with using imaging scans or assays that track the variant allele fraction (VAF) of somatic mutations in circulating tumor DNA (ctDNA) for response monitoring, we developed a tumor-naive liquid biopsy assay that leverages quantitative counting template (QCT) technology to accurately and precisely quantify methylated ctDNA (Northstar ResponseTM). Northstar ResponseTM achieves <10% coefficient of variation at 1% tumor fraction, which is 2x lower than VAF-based response monitoring approaches. The assay accurately distinguishes 0.25% absolute changes in contrived tumor fraction (AUC > 0.94) and performs well in 12 solid tumor types. Preliminary clinical results from patients with lung, colorectal, or pancreatic cancer demonstrate that Northstar ResponseTM detects changes in ctDNA methylation that correlate with clinical outcomes. As a novel tool for therapy response monitoring, the assay’s serial measurements of ctDNA methylation can be precise, reflect clinical outcomes, and have potential to inform clinical decision making for cancer treatment.
Competing Interest Statement
PY, RV, KS, SL, XB, WZ, JW, JZ, DT, and OA are employees of BillionToOne and/or hold stock or options to hold stock in the company. Patent disclosures about this work have been filed with BillionToOne, Inc. BillionToOne, Inc. funded portions of this study.
Funding Statement
This study was funded by BillionToOne, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of California San Diego gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The ability to share primary sequence data was not included in the informed consent signed by subjects. A data use agreement is required to access the data.
